tiprankstipranks
Trending News
More News >

Entero Therapeutics CSO Resigns Amid Cost-Cutting Strategy

Entero Therapeutics CSO Resigns Amid Cost-Cutting Strategy

Confident Investing Starts Here:

The latest announcement is out from Entero Therapeutics (ENTO).

Entero Therapeutics, Inc. announced that Dr. Jack Syage, the Chief Scientific Officer, has resigned from his position effective immediately as part of the company’s cost-cutting measures. However, he will maintain his roles as President and Board member. Dr. Syage has agreed to a reduced annual salary of $66,560 starting July 1, 2024, but all other compensation and employment terms remain unchanged. His resignation is not due to disagreements with the company’s direction or practices.

For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App